Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGiC: Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
NCT01197417Phase 3Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Magnesium Group with Placebo Group (2 arms). Primary endpoint: Hospital Length of Stay up to 10 days. Started Dec 2010; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01197417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197417.